SP momentum, page-2

This should have been at least 80-90c yesterday ... 10c /share in cash received and it removes the need for a cap raising which I think was depressing the shareprice at least 5-10c a share.

I think sustainability in cash flows however still remains the big catalysts that will send us north of $1-$1.50 range. That should come from BV once done and hopefully higher once sales volumes get momentum.

Also Oncology and focusing the strategy on DEP is being massively undervalued - once we get phase i results and move into phase ii - it should re-rate not just docetaxol but the whole viability of the oncology portfolio.

Let's hope we get through these stages before we get taken over